Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease (NCT07646197) | Clinical Trial Compass
RecruitingNot Applicable
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Disease
United States125 participantsStarted 2026-06-09
Plain-language summary
The aim of this randomized interventional trial is to understand the effects of peanut consumption on patients with metabolic associated fatty liver. The main goal is to investigate if patients who consume peanuts have improved liver marker tests as well as metabolic profile. We will also investigate how peanuts alter the gut microbes and liver fat content in patients with metabolic associated fatty liver.
* Participants will be randomized into intervention (peanut consumption for 12 weeks) and control (regular diet) arm.
* Stool sample and blood (for biomarkers) collection across both arms at baseline and post-intervention
* Daily log to be completed for tracking peanut consumption
* 2-day Dietary recall at baseline, during Week 6 and Week 12
* Poat intervention Fibro scans for participants with baseline scans available
Who can participate
Age range
30 Years – 70 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* 30-70 years
* do not consume peanut/peanut butter/treenut/seeds \> /week
* at least one encounter-related (stage F0/F1) MASLD diagnosis (K76.0)
* Able to understand, speak, and read English
* Mentally competent to consent
Exclusion Criteria:
* Food allergy to peanuts or peanut-containing products
* With alcohol use disorder (AUDIT screening)
* Leukemia
* Lymphoma
* Other types of cancer
* Heart or cardiovascular diseases (such as heart attack, stroke, heart failure)
* Kidney diseases (such as chronic kidney disease, kidney transplant, renal insufficiency such as renal failure requiring dialysis)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Hepatic Markers
Timeframe: Baseline to post-intervention (12 weeks)